Exclusive Summary

• - Globally fully genericized with patents long expired; 0.5% multi-dose and single-use packs address outpatient and peri-operative needs.
• - Quantified demand (1–3% annual incidence of conjunctivitis, 25–30M cataract surgeries/year, 140M contact-lens users at keratitis risk) supports steady volumes.
• - As a fourth-generation fluoroquinolone, it holds first-line/empirical status with convenient dosing and strong corneal penetration aligned with major guidelines.
• - API meets BP/USP/EP/Ph.Int., enabling Q1/Q2/Q3 sameness filings for faster access and hospital tenders across multiple jurisdictions.
• - Delivers 60–85% cost savings vs originator; single-use vials reduce wastage and fit tender packs—Vietnam requires non-China-agency route.